{'52WeekChange': -0.115449905,
 'SandP52WeekChange': 0.0644362,
 'address1': '195 Church Street',
 'address2': '14th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.34,
 'askSize': 900,
 'averageDailyVolume10Day': 48437,
 'averageVolume': 89225,
 'averageVolume10days': 48437,
 'beta': None,
 'beta3Year': None,
 'bid': 5.24,
 'bidSize': 900,
 'bookValue': 2.624,
 'category': None,
 'circulatingSupply': None,
 'city': 'New Haven',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.87,
 'dayLow': 5.106,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.334,
 'enterpriseToRevenue': None,
 'enterpriseValue': 40610108,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.422,
 'fiftyTwoWeekHigh': 8.49,
 'fiftyTwoWeekLow': 1.33,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3625055,
 'forwardEps': -1.87,
 'forwardPE': -2.8021388,
 'fromCurrency': None,
 'fullTimeEmployees': 19,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.07485,
 'heldPercentInstitutions': 0.95045,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/trevitherapeutics.com',
 'longBusinessSummary': 'Trevi Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of nalbuphine ER to treat '
                        'serious neurologically mediated conditions. The '
                        "company's nalbuphine ER, which is in Phase IIb/III "
                        'clinical trial is an oral extended release '
                        'formulation of nalbuphine that is used for the '
                        'treatment of chronic pruritus, chronic cough in '
                        'patients with idiopathic pulmonary fibrosis, and '
                        'levodopa-induced dyskinesia in patients with '
                        "Parkinson's disease. Trevi Therapeutics, Inc. was "
                        'founded in 2011 and is headquartered in New Haven, '
                        'Connecticut.',
 'longName': 'Trevi Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 93500456,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_225357348',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -29075000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.34,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '203-304-2499',
 'previousClose': 5.34,
 'priceHint': 2,
 'priceToBook': 1.9969511,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.87,
 'regularMarketDayLow': 5.106,
 'regularMarketOpen': 5.34,
 'regularMarketPreviousClose': 5.34,
 'regularMarketPrice': 5.34,
 'regularMarketVolume': 46108,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17843600,
 'sharesPercentSharesOut': 0.0034,
 'sharesShort': 60831,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 838,
 'shortName': 'Trevi Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0121,
 'shortRatio': 0.44,
 'startDate': None,
 'state': 'CT',
 'strikePrice': None,
 'symbol': 'TRVI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.813,
 'twoHundredDayAverage': 4.2314677,
 'volume': 46108,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.trevitherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '06510'}